Free Trial
→ SpaceX IPO hides a much bigger story (From Weiss Ratings) (Ad)tc pixel
NYSE:BHVN

Biohaven Q1 2025 Earnings Report

Biohaven logo
$10.07 +0.36 (+3.75%)
Closing price 03:59 PM Eastern
Extended Trading
$9.87 -0.20 (-2.02%)
As of 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Biohaven EPS Results

Actual EPS
-$1.94
Consensus EPS
-$1.94
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Biohaven Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.41 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biohaven Announcement Details

Quarter
Q1 2025
Date
8/11/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Biohaven's Q2 2026 earnings is estimated for Monday, May 11, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Biohaven's Q1 2025 Press ReleasePress Release
(8-K)
Biohaven's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Biohaven Earnings Headlines

Biohaven Expands At-The-Market Equity Offering Program
May 5 at 6:11 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/biohaven-expands-at-the-market-equity-offering-program?utm_source=marketbeat.com&utm_medium=referral
A Look At Biohaven (BHVN) Valuation After Narrower Q1 Loss And New Pivotal Trial And Funding Plans
May 5 at 6:17 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/look-biohaven-bhvn-valuation-narrower-043551450.html
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
May 6 at 1:00 AM  |  Brownstone Research (Ad)
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
May 4 at 4:02 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biohaven-reports-recent-business-developments-and-first-quarter-2026-financial-results-302761656.html
Moderate Buy Rating Seen For Biohaven Ltd. (BHVN)
April 22, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/moderate-buy-rating-seen-for-biohaven-ltd-bhvn-1743271/
Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating
April 19, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/canaccord-initiates-coverage-of-biohaven-ltd-bhvn-with-a-buy-rating-1741349/
See More Biohaven Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biohaven? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biohaven and other key companies, straight to your email.

About Biohaven

Biohaven (NYSE:BHVN) (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine. Its lead product, rimegepant—commercially marketed under the name NURTEC® ODT—has been approved for both acute migraine relief and migraine prevention in adults. Biohaven’s pipeline also includes atogepant, a once-daily oral CGRP receptor antagonist in late-stage development for migraine prevention, as well as earlier-stage candidates targeting N-methyl-D-aspartate (NMDA) receptors for chronic pain and other neurological disorders.

In addition to its internal programs, Biohaven has established global licensing agreements and co-development partnerships to expand the reach of its migraine therapies in key markets such as Europe, Canada and Asia. The company leverages a hybrid model of in-house development and external collaborations to accelerate clinical progress and broaden patient access.

Under the leadership of Founder and Chief Executive Officer Dr. Vlad Coric, Biohaven has built a multidisciplinary management team with deep experience in neuroscience drug development and commercial operations. Together, they aim to advance the company’s portfolio through late-stage clinical trials and regulatory submissions, with the goal of delivering novel treatments that improve patient outcomes in neurological and central nervous system disorders.

View Biohaven Profile
Earnings Tools